Form 4: Dyne Therapeutics CSO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.
Summary
- Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,598 shares of common stock on February 18, 2025, at a price of $13.95 per share.
- The sale was to satisfy tax withholding obligations related to the vesting of restricted stock units granted on November 15, 2023.
- The transaction was reported late due to an administrative error.
- Following the transaction, Beskrovnaya directly owns 199,087 shares, including 160,065 unvested RSUs.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The sale is related to tax obligations, which is a normal occurrence. The administrative error is a minor negative.
Negatives
- The transaction was reported late due to an administrative error.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and do not necessarily indicate a negative outlook on the company's future.
Stakeholder Impact
- The sale of shares by a company executive could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| November 15, 2023 | Date of restricted stock unit grant to Oxana Beskrovnaya |
| February 18, 2025 | Date of share sale transaction |
| February 25, 2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.